Skip to main content

Summit Therapeutics Inc. (SMMT) Stock

Summit Therapeutics Inc. Stock Details, Movements and Public Alerts

Stock Details

Summit Therapeutics Inc. (SMMT), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NGM.Currently, the stock is trading at $15.48. Over the past 52 weeks, it has ranged between $12.07 and $29.23. This places the current price at 53.0% of its 52-week high and 28.3% above its 52-week low. Recent trading volume was recorded at 3,209,684. The 14-day Relative Strength Index (RSI) stands at 45.28, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $15.79 by 1.96%. Similarly, it is below its 200-day moving average of $16.24 by 4.68%. The MACD histogram is -0.15, indicating bearish momentum (MACD Line: -0.21, Signal Line: -0.05). There are currently 4 active alerts set for SMMT by users.

52-Week Range

$29.23 - $12.07

-47.04% from high · +28.25% from low

Avg Daily Volume

7,063,510

20-day average

100-day avg: 5,752,422

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-13.11

Price to Book

19.48

EV/EBITDA

-13.34

EPS (TTM)

-$1.11

Beta

-1.52

Less volatile than market

Q:How is SMMT valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is SMMT's risk profile compared to the market?
With a beta of -1.52, Summit Therapeutics Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 19.48 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-874,670,016

Return on Equity

-192.50%

Return on Assets

-101.61%

Q:How profitable and efficient is SMMT's business model?
Profitability metrics are not available for this stock.
Q:What are SMMT's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$12.3B

Shares Outstanding

797.75M

Book Value/Share

$0.79

Asset Type

EQUITY

Q:What is SMMT's market capitalization and position?
Summit Therapeutics Inc. has a market capitalization of $12.3B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 797.75M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does SMMT's price compare to its book value?
Summit Therapeutics Inc.'s book value per share is $0.79, while the current stock price is $15.48, resulting in a price-to-book (P/B) ratio of 19.50. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$30.29

95.66% upside potential

Analyst Recommendations

Strong Buy

1

Buy

10

Hold

6

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for SMMT?
17 analysts cover SMMT with 65% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $30.29 implies 95.7% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on SMMT?
Current analyst recommendations:1 Strong Buy, 10 Buy, 6 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 24, 2026, 02:19 AM

Technical Indicators

RSI (14-day)

45.28

Neutral

50-Day Moving Average

$15.79

-1.96% below MA-50

200-Day Moving Average

$16.24

-4.68% below MA-200

MACD Line

-0.21

MACD Signal

-0.05

MACD Histogram

-0.15

Bearish

Q:What does SMMT's RSI value tell investors?
The RSI (Relative Strength Index) for SMMT is currently 45.28, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret SMMT's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.21 below the signal line at -0.05, with histogram at -0.15. This bearish crossover indicates downward pressure. The 50-day MA ($15.79) is below the 200-day MA ($16.24), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Oct 24, 2026, 12:50 AM

Active Alerts

Alert Condition
Price falls below
Threshold
$11.40
Created
Aug 29, 2026, 12:10 PM
Alert Condition
Price falls below
Threshold
$11.40
Created
Aug 29, 2026, 12:01 PM
Alert Condition
Price falls below
Threshold
$11.55
Created
Aug 13, 2026, 03:39 PM
Alert Condition
Price falls below
Threshold
$11.55
Created
Aug 13, 2026, 03:23 PM

Stay Ahead of the Market with Summit Therapeutics Inc. Alerts

Set up price alerts for Summit Therapeutics Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.